ArticleFrontiers in immunology2021

A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.

Jie Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.